In recent years, anti-VEGF therapy for wet age-related macular degeneration has made revolutionary progress. Although anti-VEGF therapy achieved exciting results, some problems and potential risks of over anti-VEGF therapy have been observed in clinical trials, which should be noticed by every ophthalmologists.
|
